Floatz logo

Giredestrant

Ovarian Cancer

Hoffmann-La RocheSmall moleculePhase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
59/ 100

Competitive context

512 Active assets in the Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Cis-Diamminedichloroplatinum Ii
Kalinski, Pawel, MD, PhD
Phase 3BB
Adriamycin
Genmab
Phase 3BB

View all 50 →

Same molecule, other indications

Giredestrant is also rated in:

estrogen-receptor positive breast cancerActive
BB
Indicative · Phase 3
70 / 100
View asset →
breast cancerActive
B
Indicative · Phase 3
63 / 100
View asset →
breast carcinomaActive
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →